



PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce, Govt. of India)

COPY

Date : 23-07-2010

News / Story reproduced with thanks:- **Business Standard**

Wockhardt gets US FDA approval for generic version of ToprolXL

Press Trust of India / Bangalore July 23, 2010, 15:06 IST

Direct link to the News/Story:-

<http://www.business-standard.com/india/news/wockhardt-gets-us-fda-approval-for-generic-versionoftoprolxl/102559/on>

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25 mg, 50mg, 100mg and 200mg extended-release tablets of Metoprolol succinate, a cardiac drug.

Metoprolol Succinate, a generic name for the brand Toprol XL, was used for 24-hour control of hypertension, treatment of angina and in improving survival after heart attack, a company press release said.

The product is being launched immediately.

Metoprolol succinate extended release was one of the most widely prescribed hypertension and angina drugs valued at over \$1.1 billion in the United States. Wockhardt would be the second generic version of this technically demanding product in the US market, apart from the brand and its authorised generic, it said.

The tablets will be manufactured at the US FDA certified formulation plant at Aurangabad, where they are developed in-house.

Metoprolol succinate extended release is one of the most widely prescribed hypertension and angina drugs valued at over USD 1.1 billion in the United States. Wockhardt will be only the second generic version of this technically demanding product in the US market, apart from the brand and its authorized generic.

In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all of its products.

The tablets will be manufactured at the US FDA certified formulation plant at Aurangabad in Maharashtra. The tablets were developed in-house.

Wockhardt is a technology-driven pharmaceutical and biotechnology company with an active multi-disciplinary research programme employing over 500 scientists. Its new drug discovery programme has yielded several promising lead molecules, one of which is now in Phase II human clinical trials. The US and European Union contribute to around 69 per cent of Wockhardt's sales.